Phaseline

Targets › OPN4

OPN4 (Melanopsin): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 4; Neurology; next expected readout Dec 2026.

G protein-coupled photoreceptor that signals through the G(q/11) family of G proteins in response to light in intrinsically photosensitive retinal ganglion cells (ipRGCs) (By similarity). Can also activate other G proteins, including G(i/o) and G(s), depending on the cell type, leading to either activation or inhibition of adenylate cyclase and cAMP-dependent signaling. (UniProt, Q9UHM6)

Open in Phaseline: the race on OPN4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of HealthBlue light exposure
Photoentrainment via intrinsically photosensitive retinal ganglion cells
OPN4Phase 4Ischemic Stroke, AcuteDec 2026

Conditions

Ischemic Stroke, Acute (1)

Modalities

small molecule (1)

Companies

Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.